Solstar Pharma announces the publication of its patent related to H. pylori


We are pleased to announce that our first patent is available online today and has been officially published on December 30, 2020 under number WO2020257936: “EXTENDED RELEASE GASTRORETENTIVE FORMULATION AGAINST HELICOBACTER PYLORI.” Our formulated water-soluble active pharmaceutical ingredients were developed to address the issue of antibiotic-resistant H. pylori infections.

You can click here to learn more about our formulated APIs: Water soluble APIs

Helicobacter pylori (H. pylori) is a bacterium that grows in the inner lining of the stomach. H. pylori can cause long-lasting inflammation of the inner lining of the stomach (gastritis) and stomach ulcers. It is also a main cause of stomach cancer and some types of lymphoma of the stomach.

H. pylori can be found in about half of the world’s population. Generally, H. pylori infection rates are higher in developing countries than in developed countries. People infected with H. pylori are usually given a combination of antibiotics and a drug to help reduce acid in the stomach for 7 to 14 days.

However, antibiotic resistance is rising to dangerously elevated levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. H. pylori infections are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.

Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.

At Solstar Pharma, we are developing new ways to attack antibiotic-resistant infections. We are developing non-antibiotic antimicrobials formulated with our patented solubility technology. These water-soluble bioactive agents have the potential to attack antibiotic-resistant bacteria by using different mechanisms of action than conventional antibiotics thereby preventing resistance to be gained to our technology.